References
1. Linkens AEMJH, Milosevic V, van der Kuy PHM, et al.
Medication-related hospital admissions and readmissions in older
patients: an overview of literature. Int J Clin Pharm.
2020;42(5):1243–51; https://doi.org/10.1007/s11096-020-01040-1.
2. Wallerstedt SM, Hoffmann M, Lönnbro J. Methodological issues in
research on drug-related admissions: A meta-epidemiological review with
focus on causality assessments. Br J Clin Pharmacol. 2022 Feb
1;88(2):541–50; https://doi.org/10.1111/bcp.15012.
3. El Morabet N, Uitvlugt EB, van den Bemt BJF, et al. Prevalence and
Preventability of Drug-Related Hospital Readmissions: A Systematic
Review. J Am Geriatr Soc. 2018 Mar 1;66(3):602–8;
https://doi.org/10.1111/jgs.15244.
4. Ayalew MB, Tegegn HG, Abdela O. Drug Related Hospital Admissions; A
Systematic Review of the Recent Literatures. Bull Emerg Trauma.
2019;7(4):339–46; https://doi.org/10.29252/beat-070401.
5. PCNE. PCNE Classification for Drug-Related Problems V9.1
[Internet]. Pharmaceutical Care Network Europe Association. 2020
[cited 2022 Jan 7]. p. 10. Available from:
https://www.pcne.org/working-groups/2/drug-related-problem-classification
6. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis. 1987;40(5):373–83;
https://doi.org/10.1016/0021-9681(87)90171-8.
7. García-Pérez L, Linertová R, Lorenzo-Riera A, et al. Risk factors for
hospital readmissions in elderly patients: a systematic review. QJM An
Int J Med. 2011 Aug 1;104(8):639–51;
https://doi.org/10.1093/qjmed/hcr070.
8. Lea M, Mowe M, Mathiesen L, et al. Prevalence and risk factors of
drug-related hospitalizations in multimorbid patients admitted to an
internal medicine ward. PLoS One. 2019 Jul 22;14(7):e0220071;
https://doi.org/10.1371/journal.pone.0220071.
9. Nymoen LD, Björk M, Flatebø TE, et al. Drug-related emergency
department visits: prevalence and risk factors. Intern Emerg Med. 2022;
https://doi.org/10.1007/s11739-022-02935-9.
10. Christensen M, Lundh A. Medication review in hospitalised patients
to reduce morbidity and mortality. Cochrane Database Syst Rev.
2016;CD008986; https://doi.org/10.1002/14651858.CD008986.pub3.
11. Kempen TGH, Bertilsson M, Hadziosmanovic N, et al. Effects of
Hospital-Based Comprehensive Medication Reviews Including Postdischarge
Follow-up on Older Patients’ Use of Health Care: A Cluster Randomized
Clinical Trial. JAMA Netw Open. 2021 Apr 30;4(4):e216303–e216303;
https://doi.org/10.1001/jamanetworkopen.2021.6303.
12. Kempen TGH, Bertilsson M, Lindner K-J, et al. Medication Reviews
Bridging Healthcare (MedBridge): Study protocol for a pragmatic
cluster-randomised crossover trial. Contemp Clin Trials. 2017
Oct;61:126–32; https://doi.org/10.1016/j.cct.2017.07.019.
13. Kempen TGH, Hedström M, Olsson H, et al. Assessment tool for
hospital admissions related to medications: development and validation
in older patients. Int J Clin Pharm. 2019;41(1);
https://doi.org/10.1007/s11096-018-0768-8.
14. Howard RL, Avery AJ, Howard PD, et al. Investigation into the
reasons for preventable drug related admissions to a medical admissions
unit: observational study. Qual Saf Heal Care. 2003 Aug;12(4):280–5;
https://doi.org/10.1136/qhc.12.4.280.
15. Hepler CD, Strand LM. Opportunities and responsibilities in
pharmaceutical care. Am J Hosp Pharm. 1990 Mar;47(3):533–43.
16. European Association for the Study of the Liver. EASL Clinical
Practice Guidelines for the management of patients with decompensated
cirrhosis. J Hepatol. 2018;69(2):406–60;
https://doi.org/10.1016/j.jhep.2018.03.024.
17. Weersink RA, Burger DM, Hayward KL, et al. Safe use of medication in
patients with cirrhosis: pharmacokinetic and pharmacodynamic
considerations. Expert Opin Drug Metab Toxicol. 2020 Jan 2;16(1):45–57;
https://doi.org/10.1080/17425255.2020.1702022.
18. Alassaad A, Melhus H, Hammarlund-Udenaes M, et al. A tool for
prediction of risk of rehospitalisation and mortality in the
hospitalised elderly: secondary analysis of clinical trial data. BMJ
Open. 2015 Feb 1;5(2):e007259;
https://doi.org/10.1136/bmjopen-2014-007259.
19. Leendertse AJ, Egberts ACG, Stoker LJ, et al. Frequency of and risk
factors for preventable medication-related hospital admissions in the
Netherlands. Arch Intern Med. 2008 Sep;168(17):1890–6;
https://doi.org/10.1001/archinternmed.2008.3.
20. Wimmer BC, Dent E, Bell JS, et al. Medication Regimen Complexity and
Unplanned Hospital Readmissions in Older People. Ann Pharmacother. 2014
May 27;48(9):1120–8; https://doi.org/10.1177/1060028014537469.
21. Tsuyuki RT, McKelvie RS, Arnold JMO, et al. Acute Precipitants of
Congestive Heart Failure Exacerbations. Arch Intern Med. 2001 Oct
22;161(19):2337–42; https://doi.org/10.1001/archinte.161.19.2337.
22. Goyal P, Kneifati-Hayek J, Archambault A, et al. Prescribing
Patterns of Heart Failure-Exacerbating Medications Following a Heart
Failure Hospitalization. JACC Hear Fail. 2020;8(1):25–34;
https://doi.org/10.1016/j.jchf.2019.08.007.
23. Katzenberg G, Deacon A, Aigbirior J, et al. Management of chronic
obstructive pulmonary disease. Br J Hosp Med. 2021 Jul 2;82(7):1–10;
https://doi.org/10.12968/hmed.2020.0561.
24. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive
pulmonary disease exacerbation and inhaler device handling: real-life
assessment of 2935 patients. Eur Respir J. 2017 Feb 1;49(2):1601794;
https://doi.org/10.1183/13993003.01794-2016.
25. Klatte DCF, Gasparini A, Xu H, et al. Association Between Proton
Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
Gastroenterology. 2017;153(3):702–10;
https://doi.org/10.1053/j.gastro.2017.05.046.
26. Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy
with proton pump inhibitors and risk of gastric cancer: a nationwide
population-based cohort study in Sweden. BMJ Open. 2017 Oct
1;7(10):e017739; https://doi.org/10.1136/bmjopen-2017-017739.
27. Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump
inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol.
2018;53:172–7; https://doi.org/10.1016/j.canep.2018.02.004.
28. Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the
treatment of heart failure: a major issue to tackle. Heart Fail Rev.
2021;26(6):1359–70; https://doi.org/10.1007/s10741-020-09979-z.
29. Cooke CE, Sidel M, Belletti DA, et al. Review: clinical inertia in
the management of chronic obstructive pulmonary disease. COPD. 2012
Feb;9(1):73–80; https://doi.org/10.3109/15412555.2011.631957.
30. Kempen TGH, Cam H, Kälvemark A, et al. Intervention fidelity and
process outcomes of medication reviews including post-discharge
follow-up in older hospitalized patients: process evaluation of the
MedBridge trial. J Clin Pharm Ther. 2020 Mar 14;
https://doi.org/10.1111/jcpt.13128.